MediPharm Labs has announced that David Pidduck will be stepping down from his role as the Company's Chief Executive Officer, effective January 23rd, 2026. The Board of Directors has appointed Greg Hunter, the Company's Chief Financial Officer, as Interim Chief Executive Officer, while it evaluates its long‑term leadership plans. Mr. Hunter will continue to serve as Chief Financial Officer during this interim period.
In a statement, the company said: "The board is pleased to appoint Mr. Hunter as Interim Chief Executive Officer. Since assuming the Chief Financial Officer role in February 2021, he has implemented meaningful cost‑reduction initiatives and strengthened financial and operational controls. He has also been deeply involved in commercial strategy, working closely with the sales, marketing, and product teams to enhance pricing, support key customer programs, negotiate improved commercial terms, and ensure manufacturing and supply capabilities align with market demand. His cross‑functional leadership has contributed to stronger execution, improved margins, and a more competitive commercial position."
Chris Taves, Chair of the Board, commented: "On behalf of the Board and the entire MediPharm Labs team, I want to thank David for his significant contributions. His leadership played a key role in strengthening MediPharm's financial trajectory and guiding the Company through challenging market conditions. We are equally pleased to have a seasoned leader like Greg step into the Interim CEO role during this transition and the Board is confident in his ability to drive execution, operational discipline, and focused growth in the months ahead."
For more information:
MediPharm Labs
medipharmlabs.com
